or duration in 41 of 44 patients tested (93%)...

ReVision's Fenretinide (RT-101) Reduced Incidence Of Choroidal Neovascularization By More Than 50 Percent In Patients With Geographic Atrophy published Thu, 02 Sep 2010 02:00:00 PDT
ReVision Therapeutics Inc. announced that data from a Phase 2b trial show that fenretinide (RT-101) reduced the incidence of choroidal neovascularization (CNV, wet age related macular degeneration) by about 50 percent in patients with geographic atrophy (GA), the most advanced form of dry age related macular degeneration (AMD). The data, presented Monday by Alexander M. Eaton, M.D...

Microplasmin Meets Primary Endpoint In Second Phase III Trial In VMA, Confirms Positive Findings Of First Trial published Thu, 02 Sep 2010 02:00:00 PDT
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint...

pSivida Announces Iluvien(R) Receives FDA Priority Review For Treatment Of Diabetic Macular Edema published Thu, 02 Sep 2010 01:00:00 PDT
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, announced that its licensee, Alimera Sciences (NASDAQ:ALIM) has been notified that the U.S...

Allergan Receives FDA Approval For LUMIGAN(R) 0.01% As First-Line Therapy Indicated For The Reduction Of Elevated Intraocular Pressure In Glaucoma published Thu, 02 Sep 2010 00:00:00 PDT
Allergan, Inc. (NYSE:AGN) announced the United States Food and Drug Administration (FDA) has approved LUMIGAN® (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. LUMIGAN® 0...

Improving Ocular Disease Screening By LED Illumination Of The Eye published Wed, 01 Sep 2010 04:00:00 PDT
A new imaging system using six different wavelengths to illuminate the interior of the eyeball (ocular fundus) may pave the way for doctors to easily screen patients for common diseases of the eye, such as age-related macular degeneration and diabetic retinopathy. The system is described in the journal Review of Scientific Instruments, which is published by the American Institute of Physics...

Eyegenix™ Artificial Cornea Achieves Major Advancement Towards Curing Corneal Blindness published Wed, 01 Sep 2010 02:00:00 PDT
Eyegenix™, the ophthalmic division of Cellular Bioengineering, Inc. (CBI), announced that the results of a pilot clinical trial using a synthetic cornea for which Eyegenix™ holds the exclusive global license for transplantation were published in the peer-reviewed journal, Science Translational Medicine (Volume 2, Issue 46, August, 25, 2010)...

Diabetic Macular Edema Drug Iluvien Gets FDA Priority Review published Tue, 31 Aug 2010 08:00:00 PDT
Iluvien(R) (fluocinolone acetonide intravitreal insert), an investigational sustained drug delivery system that releases sub-microgram levels of fluocinolone acetonide for DME (diabetic macular edema) treatment, has been accepted for filing and granted Priority Review States by the FDA (Food and Drug Administration, USA), Alimera Sciences, Inc. announced today...

Optometrists Encourage Eye Test For Children, Ireland published Tue, 31 Aug 2010 04:00:00 PDT
Optometrists are encouraging parents and teachers across the country to take their children for a special eye test as part of its Bright Eyes For Back to School campaign which runs next week (from September 6th to 11th)...

'Toolbox Of MiniPromoters' For Gene Research And Therapy Unvelied By UBC Researchers published Tue, 31 Aug 2010 04:00:00 PDT
University of British Columbia researchers have led the development of a new "toolbox of MiniPromoters" for research and future therapies on brain, spinal cord and eye function. MiniPromoters are small segments of human DNA with the ability to turn genes on and off at specific times and locations...

Revolutionary Way To Treat Eye Cancer May Prevent Blindness published Tue, 31 Aug 2010 00:00:00 PDT
Rare but devastating, eye cancer can strike anyone at any time and treating it often requires radiation that leaves half of all patients partially blind. But a new technique developed by Scott Oliver, MD, assistant professor at the University of Colorado School of Medicine, may change all that...

Seeking Quality Education For Deaf Blind Children In Today's Environment published Sat, 28 Aug 2010 01:00:00 PDT
Deaf blind children can be isolated and disconnected from people and activities. Without individualized support, they cannot access visual and auditory information and often complete school unable to seek future education, employment, or independent living. Providing appropriate special education and related services for deaf blind children poses unique challenges...

Vision And Nerve Growth Restored By Biosynthetic Corneas Formulated With Recombinant Collagen published Sat, 28 Aug 2010 00:00:00 PDT
FibroGen, Inc., has announced results of a 2-year clinical study demonstrating that surgical implantation of biosynthetic corneas formulated with the company's proprietary recombinant human type III collagen (rhCIII) restored vision and promoted nerve regeneration (restoring sensitivity) in patients who had corneal damage and significant vision loss...

)

Home l Contact l